Pfizer Inc. has seen its earnings and revenue grow drastically in recent quarters, driven largely by sales of its COVID-19 vaccine. However, from its latest reporting period, Pfizer Inc. reported Q4 FY 2021 earnings that smashed analyst expectations.
Adjusted earnings per share (EPS) rose 151.2% compared to the year-ago quarter, beating expectations by a wide margin. Pfizer’s revenue expanded 104.9% year over year, matching analyst forecasts.
Approximately 58% of this revenue was from vaccine sales, including sales of the company’s COVID-19 vaccine, developed with German-based BioNTech SE.
Pfizer’s shares were down nearly 4% in pre-market trading. Over the past year, Pfizer’s stock has provided a total return of 58.3%, well above the S&P 500’s total return of 14.5%.3
Pfizer’s revenue growth decelerated from the previous quarter’s rapid pace, but it was still the second-fastest pace of growth in at least 15 quarters. It was primarily driven by sales of two products related to COVID-19: Comirnaty, the company’s vaccine against the disease; and Paxlovid, its new oral antiviral treatment against COVID-19. Comirnaty contributed $12.5 billion to the company’s total revenue, while Paxlovid contributed $76 million. Excluding sales from Comirnaty and Paxlovid, Pfizer’s revenue declined by 2% operationally (operational revenue excludes the impact of foreign exchange rates). Pfizer said that the decline was primarily due to having fewer selling days compared to the year-ago quarter.
According to Zerohedge:
Two weeks ago, the FDA begged a Texas judge to delay production on the first monthly batch of 55,000 pages of Covid-19 vaccine data submitted to the agency by Pfizer. Originally, the agency was set to produce just 500 pages-per-month.
Now, Pfizer – which just forecast $54 billion in Covid-related sales in 2022, appears to be anticipating some bad news, as evidenced by several redline changes in their Q4 earnings releases.
Here are the Provide Updates about Pfizer reports fourth-quarter and full-year 2021 results:
Pfizer added new and peculiar items deep in its business risk disclosures re: clinical trial data, today in its Q4 earnings.
(1/3)
“…risks associated with…further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection;” pic.twitter.com/2GCjs0Bj3r— Kelly Brown (@rubiconcapital_) February 8, 2022
(2/3)
“…challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, CONCERNS ABOUT CLINICAL DATA INTEGRITY and prescriber and pharmacy education;”(all-caps are mine) pic.twitter.com/bAKH4iqiKs
— Kelly Brown (@rubiconcapital_) February 8, 2022
(2/3)
“…challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, CONCERNS ABOUT CLINICAL DATA INTEGRITY and prescriber and pharmacy education;”(all-caps are mine) pic.twitter.com/bAKH4iqiKs
— Kelly Brown (@rubiconcapital_) February 8, 2022
In a report by The Epoch times:
Pfizer is still forecasting roughly $54 billion in sales for the fiscal year of 2022:
The American pharmaceutical and biotechnology giant said it expects to sell $32 billion of its vaccinations and $22 billion of its antiviral COVID-19 treatment pill Paxlovid in 2022 as demand for the products continues.
Pfizer said, those numbers are based on contracts signed or close to being signed as of late January.
Sources: Welovetrump, Zerohedge, Theepochtimes
Thomas Cooper